Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.
Send In The Senolytics
- By SRF staff
- November 17, 2020
- 9:50 am
Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

- By SRF staff
- November 17, 2020
- 9:50 am
Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on google
Share on email
Latest Posts:
Job Opportunity: Research Associate (Immunology)
SRF staff March 16, 2021 10:27 am
SRF Masks Available
SRF staff March 4, 2021 12:14 pm
WebMD Feature: Is There a Cure for Aging?
SRF staff February 16, 2021 3:19 pm
Enriching Mitochondria
SRF staff February 9, 2021 2:39 pm
Undoing Aging is rescheduled to May 26-28, 2022
SRF staff January 28, 2021 10:00 pm
Antonov Foundation donates $1M to SRF’s End of Year Campaign
SRF staff January 16, 2021 12:59 am
Parabiosis: the Dilution Solution?
Michael Rae January 11, 2021 11:08 am
Send In The Senolytics
SRF staff November 17, 2020 9:50 am
Tracking Down Glucosepane
SRF staff October 6, 2020 3:19 pm
A Letter to the Economist
SRF staff September 24, 2020 2:36 am
Defatting the Streaks
SRF staff August 12, 2020 10:08 am